CA125 suppresses amatuximab immune-effector function and elevated serum levels are associated with reduced clinical response in first line mesothelioma patients

The tumor-shed antigen CA125 has recently been found to bind certain monoclonal antibodies (mAbs) and suppress immune-effector mediated killing through perturbation of the Fc domain with CD16a and CD32a Fc-γ activating receptors on immune-effector cells. Amatuximab is a mAb targeting mesothelin whos...

Descripción completa

Detalles Bibliográficos
Autores principales: Nicolaides, Nicholas C., Schweizer, Charles, Somers, Elizabeth B., Wang, Wenquan, Fernando, Shawn, Ross, Erin N., Grasso, Luigi, Hassan, Raffit, Kline, J. Bradford
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Taylor & Francis 2018
Materias:
Research Paper
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5989791/
https://www.ncbi.nlm.nih.gov/pubmed/29652548
http://dx.doi.org/10.1080/15384047.2018.1449614

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5989791/
https://www.ncbi.nlm.nih.gov/pubmed/29652548
http://dx.doi.org/10.1080/15384047.2018.1449614

Ejemplares similares